Recursion Pharmaceuticals (RXRX) Q1 2026 earnings summary

Executive summary

• Leveraged an AI-driven platform to accelerate drug discovery and development, achieving clinical proof-of-concept for REC-4881 in FAP and advancing multiple wholly owned and partnered programs with defined milestones over the next 12–18 months.

• Achieved over $500 million in partner inflows and 10+ milestones, validating the AI engine's ability to generate novel targets and molecules.

• Maintained a strong cash position of $665.2 million as of March 31, 2026, supporting operations into early 2028 without additional financing.

• Net loss for Q1 2026 narrowed to $117.5 million from $202.5 million year-over-year, reflecting improved operational efficiency and reduced expenses.

• Appointment of Dr. Vicki Goodman as Chief Medical Officer to lead clinical development and regulatory strategy.

Financial highlights

• Total revenue for Q1 2026 was $6.5 million, down 56% year-over-year due to lower milestone recognition.

• Cash operating expenses reduced by ~30% year-over-year to $85.1 million in Q1 2026, with R&D and G&A expenses also significantly lower.

• Cash, cash equivalents, and restricted cash totaled $665.2 million as of March 31, 2026.

• Net loss per share improved to $(0.22) from $(0.50) year-over-year.

• Maintained 2026 cash OpEx guidance of less than $390 million, fully funding expected milestones and partnerships.

Outlook and guidance

• Cash runway expected to last into early 2028 without additional financing, based on current expense levels and partnership inflows.

• Multiple clinical and regulatory milestones anticipated in 2026 and 2027, including Phase 2 data, FDA engagement, and development candidate decisions with partners.

• Ongoing FDA engagement for REC-4881 in FAP, with additional data and regulatory clarity expected in the second half of 2026.